A5026693501- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Pancreatitis Pathology and Treatment
- Cancer Cells and Metastasis
- Renal cell carcinoma treatment
- Esophageal and GI Pathology
- Gastric Cancer Management and Outcomes
- Nutrition and Health in Aging
Northwestern Medicine
2022-2024
Northwestern University
2023-2024
Objective: In this prospective study, we aim to characterize the prognostic value of circulating tumor DNA (ctDNA) by next-generation-sequencing (NGS) in patients undergoing neoadjuvant chemotherapy (NAC) for pancreatic ductal adenocarcinoma (PDAC). Summary Background Data: Circulating is a promising blood-based biomarker that several malignancies. Detection ctDNA NGS may provide insights regarding mutational profiles PDAC help guide clinical decisions potentially curative setting. However,...
Objective: The primary objective was to determine the prognostic significance of circulating tumor DNA (ctDNA) in patients receiving neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma (PDAC) using digital droplet polymerase chain reaction (ddPCR). Summary and Background Data: Increasingly, ctDNA is being used clinical decision-making a variety solid malignancies. However, detection value KRAS as assessed by ddPCR during NAC has yet be characterized. Methods:...
Abstract Introduction: The detectability and prognostic significance of circulating tumor DNA (ctDNA) in patients with pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant chemotherapy (NAC) is unclear. objective this study was to investigate the rate detection value KRAS mutant ctDNA PDAC treatment NAC as assessed by digital droplet polymerase chain reaction (ddPCR). Methods: Patients newly diagnosed, localized, were enrolled a prospective cohort study. Peripheral blood samples...
Abstract Introduction: The utility of circulating tumor DNA (ctDNA) as a biomarker in localized pancreatic ductal adenocarcinoma (PDAC) remains unclear. We aimed to characterize the detection ctDNA by targeted next-generation sequencing (NGS) during treatment for PDAC and evaluate clinical implication detection. Methods: Patients with were enrolled prospective study at Northwestern Medicine Cancer Centers between September 2020 May 2022. During treatment, blood was drawn NGS assessment...